Clinical trial · no report yet · Phase 3
SUNMO
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- NCT05171647 ↗
- Active not recruiting
- Hoffmann-La Roche
- 74 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 37 | |
| Podcasts | 19 | |
| X threads | 18 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab; Polatuzumab vedotin; Tocilizumab; Rituximab; Gemcitabine; Oxaliplatin
- Arms
- M+P (Arm A) · Experimental
- R-GemOx (Arm B) · Active comparator
- Enrollment
- 208
- Primary outcomes
- Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
- Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 25, 2022
- Primary completion
- Feb 17, 2025
- Results posted
- Yes
- Registry record
- NCT05171647 · updated Aug 5, 2026
Publications
linked from the registry- Maruyama D, Goto H, Kumode T, Aizawa K, Fukuhara N, Westin JR, Kim WS, Mori C, Imaizumi T, Kato K. Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. Int J Clin Oncol. 2026 Aug;31(8):1547-1556. doi: 10.1007/s10147-026-03042-x. Epub 2026 Jun 15. PubMed 42298056
- Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah N, Assouline S, Olszewski AJ, Naik S, Ghosh N, Pham S, Wei MC, Batlevi C, To I, Ead W, Makadia S, Penuel E, Jing J, Budde LE. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. Am J Hematol. 2026 Sep;101(9):2177-2189. doi: 10.1002/ajh.70403. Epub 2026 Jun 12. PubMed 42283231
- Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. J Clin Oncol. 2025 Dec 20;43(36):3799-3811. doi: 10.1200/JCO-25-01957. Epub 2025 Oct 2. PubMed 41037766